Compare · Research-Use-Only
BPC-157 vs GHK-Cu
BPC-157 and GHK-Cu are the two most-cited research peptides in tissue and skin recovery models. They work through different mechanisms: BPC-157 modulates growth factor pathways across multiple tissue types, while GHK-Cu acts as a copper chaperone influencing collagen synthesis and gene expression.
BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, taken from a conserved sequence within the human gastric juice protein BPC. It is unusually stable in gastric acid, plasma, and tissue (hence the name 'stable gastric pentadecapeptide'), which sets it apart from most endogenous peptides. The precise receptor has not been definitively identified. Several mechanistic pathways have been proposed and characterized in preclinical models. BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and promotes angiogenesis, the growth of new blood vessels, which may underlie its wound-healing effects in tendon, ligament, and muscle tissue. It also modulates nitric oxide (NO) production through both the constitutive (eNOS, nNOS) and inducible (iNOS) nitric oxide synthase isoforms, with context-dependent effects that help restore vascular homeostasis. BPC-157 activates focal adhesion kinase (FAK) and paxillin, two proteins critical for cell migration, adhesion, and survival. That may explain why it promotes fibroblast and keratinocyte migration in wound models. It also interacts with the GABA-B receptor system, and preclinical data suggest modulation of dopaminergic and serotonergic pathways. In gastrointestinal research, BPC-157 protects gastric mucosa by suppressing NF-κB, reducing oxidative stress, and maintaining mucosal integrity. It is notable that BPC-157 is active at very low doses (nanogram range) in most preclinical models. All mechanistic and efficacy data are currently from preclinical studies; no completed human clinical trials exist.
GHK-Cu
GHK-Cu (glycyl-L-histidyl-L-lysine copper(II)) is a naturally occurring copper-binding tripeptide, first isolated from human plasma albumin by Pickart and Thaler in 1973. It is present at concentrations of ~200 ng/mL in plasma of young adults, and declines substantially with age. The peptide holds Cu(II) through the histidine imidazole nitrogen and the N-terminal amine in a square planar complex. That copper binding is central to GHK-Cu's biological activity. The copper-peptide complex acts as a cellular copper chaperone, a carrier that hands copper to the enzymes that need it, including lysyl oxidase (collagen cross-linking), superoxide dismutase (SOD1), and cytochrome c oxidase. At the cellular level, GHK-Cu activates several signaling pathways at once. It increases synthesis of collagen types I, III, and VI in dermal fibroblasts, the skin cells that build connective tissue. It also stimulates production of glycosaminoglycans and proteoglycans and promotes fibronectin and decorin expression. These are all components of extracellular matrix remodeling, the rebuilding of the scaffold between cells. It modulates matrix metalloproteinase (MMP) activity in both directions: it increases MMP-2 and MMP-9 to clear damaged matrix, while also raising TIMP-1 and TIMP-2 to keep that remodeling in check. Gene expression analysis (Connectivity Map) shows GHK can modulate expression of over 4,000 genes, including pathways involved in inflammation (NF-κB suppression), oxidative stress (Nrf2 activation), and DNA repair. In wound healing models, GHK-Cu stimulates angiogenesis (the growth of new blood vessels) via VEGF upregulation and speeds up keratinocyte migration.
Other research peptide comparisons
Both compounds in stock at Veridian. 99%+ HPLC purity, same-day US shipping.
Browse all research peptides →